Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412620 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00412620 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 156 participants.
The verdict
NCT00412620, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders, Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or schizoaffective disorder.
Interventions
- DRUG Placebo
- DRUG ABT-925
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412620
The ClinicalTrials.gov registry entry for NCT00412620 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00412620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412620 about?
NCT00412620 is a clinical study titled "An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia". The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders, Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or schizoaffective disorder.
What is the current status of trial NCT00412620?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2006-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00412620?
The interventions under investigation include: Placebo (DRUG), ABT-925 (DRUG).
Who is sponsoring clinical trial NCT00412620?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.